Ovarian cancer is the seventh most common gynaecologic malignancy seen in women. Majority of the patients with ovarian cancer are diagnosed at the advanced stage making prognosis poor. The standard management of advanced ovarian cancer includes tumour debulking surgery followed by chemotherapy. Various types of chemotherapeutic regimens have been used to treat advanced ovarian cancer, but the most promising and the currently used standard first-line treatment is carboplatin and paclitaxel. Despite improved clinical response and survival to this combination of chemotherapy, numerous patients either undergo relapse or succumb to the disease as a result of chemotherapy resistance. To understand this phenomenon at a cellular level, various macromolecules such as DNA, messenger RNA and proteins have been developed as biomarkers for chemotherapy response. This review comprehensively summarizes the problem that pertains to chemotherapy resistance in advanced ovarian cancer and provides a good overview of the various biomarkers that have been developed in this field.
Keyphrases
- locally advanced
- end stage renal disease
- chronic kidney disease
- ejection fraction
- newly diagnosed
- chemotherapy induced
- minimally invasive
- rectal cancer
- type diabetes
- phase ii study
- clinical trial
- pregnant women
- single molecule
- skeletal muscle
- adipose tissue
- free survival
- coronary artery disease
- circulating tumor cells
- breast cancer risk
- phase iii